Abstract
Introduction
Normal colon epithelial cells, in their way to malignancy, pass through a sequence of stages, which include the formation of aberrant crypt foci (ACF), subsequently the formation of adenoma and finally carcinoma [1] . During this process of carcinogenesis genetic lesions that characterize this transition accumulate [2] .
In one of the pathways leading to colon carcinogenesis, an initial step consists of mutations on APC (adenomatous polyposis coli) gene at chromosome 5q21, the gene that is the cause of the hereditary polyposis syndrome familial adenomatous polyposis (FAP).
These lesions are already present in ACF (Fig. 1A) . [4, 5] .
For the next step that results in the formation of adenomas, activating mutations of the K-ras oncogene take place. The transition from adenoma to carcinoma requires the loss of function of tumour suppressor proteins Smad4 (alternatively called deleted in pancreatic cancer 4-DPC4) and p53 [3]. This is accomplished by mutations of one copy of the genes encoding these proteins and loss of heterozygosity (LOH) at their normal allelic loci at chromosomes 18q and 17p, respectively. This linear sequence of events causes inter-connected deregulation of cell homeostasis that culminate in the malignant phenotype by excess proliferation, inhibition of apoptosis and loss of normal anoikis (inter-cellular adhesion-dependent apoptosis). In another pathway leading to colon carcinogenesis, genes involved in DNA mismatch repair such as MSH2 (human MutS homologue 2), MLH1 (human MutL homologue 1) and PMS2 are mutated (Fig. 1B). These mutations are the cause of the hereditary colorectal cancer syndrome HNPCC (hereditary nonpolyposis colorectal cancer) and result in the microsatellite instability phenotype in which frequent frameshift mutations occur in DNA sequences characterized by nucleotide repeats throughout the genome

Mutations that are the cause of the two hereditary colorectal cancer syndromes FAP and HNPCC are present in almost 100% of sporadic cases (about 85% have a somatically mutant APC and 15% one of the HNPCC causing genes mutated).
In addition to genetic lesions epigenetic changes play a role in the pathogenesis of colorectal carcinoma [6, 7] . These changes consist of DNA methylation of promoter sequences that lead to transcription silencing and histone acetylation, methylation and phosphorylation [6] . DNA Fig. 1) and is associated more often with the microsatellite instability phenotype [8] .
methylation takes place in promoter regions rich in cytidine-phosphoguanosine (CpG) nucleotide sequences called CpG islands and leads to a phenotype known as CIMP (CpG island methylation phenotype). CpG methylation is present early in the adenoma-carcinoma evolution (
The [9] . In addition, epidemiologic studies of non-steroidal anti-inflammatory drugs (NSAIDs) have shown a positive preventive effect of Cox inhibition in both genetically predisposed people and in the general population [10] [11] [12] 
ubiquitin-proteasome system (UPS) once believed to be a cellular waste disposal basket has recently been established as an important regulatory system that modulates virtually every cell function. Its involvement in processes paramount in the establishment of neoplasia such as the cell cycle and apoptosis as well as the finding that it regulates the key antiapoptotic transcription factor NF-B has formed the basis for the exploration of proteasome inhibition as an anti-neoplastic strategy. The proteasome inhibitor bortezomib is already used in the treatment of multiple myeloma and is investigated in other cancers such as colorectal carcinoma. Cox-2 (Cyclooxygenase-2) is the inducible form of the enzyme of prostaglandins biosynthesis pathway that converts the lipid arachidonic acid to prostaglandin G2 (PGG2) and subsequently PGH2 with a peroxydase and a cyclooxygenase activity, respectively. In contrast to the 'housekeeping' Cox-1, which performs the same enzymatic activity and is expressed constitutively in most tissues, Cox-2 is not expressed at baseline but is induced by inflammation and in several types of cancer. In colorectal cancer it has been found to be up-regulated and evidence from in vitro models and in vivo knock-out and transgenic animal models point to an important role of cox-2 in colorectal carcinogenesis and carcinogenesis in other locations
. NSAIDs have now been found to possess Cox-independent antiproliferative effects in many cell types and it is possible that at least part of their cancer preventive and therapeutic effects seen in various models is Coxindependent. Nevertheless, this fact does not lessen their value as anti-neoplastic agents.
In the paragraphs that follow, pathways affected by the above genetic lesions playing important roles in colorectal carcinogenesis will be described. 20 Wnt gene analogs [13] . After Wnt ligation Frizzled activates the protein dishevelled, which in cooperation with GSK3␤ binding protein (GBP) inhibits the kinase GSK3␤ (glycogen synthase kinase-3␤) [14, 15] (Fig. 2 [16] . A mutant ␤-catenin in which serine at position 37 is changed to alanine (S37A mutant) and thus it cannot be phosphorylated at this position, cannot be ubiquitinated and degradated [17] . ␤-catenin ubiquitination is a reversible process as de-ubiquitinating 41, 42] (Fig. 3 ). In contrast an alternative inhibitory regulation of ␤-catenin not involving the ubiquitin-proteasome system is mediated by the calpain system. -calpain mediated ␤-catenin degradation may be particularly important in colorectal cancer where, due to APC mutations, proteasome-mediated regulation is defective [43] .
Afterwards the effects of Cox-2 enzyme in these critical pathways and the role of ubiquitin-proteasome
APC and the Wnt pathway
APC is a regulator of the Wnt signalling pathway. Wnt (the name derived from the fly homologue Wingless and the first mammalian family member Wnt1 initially called int-1) is a soluble factor that ligates the cell surface receptor Frizzled in co-operation with the coreceptor LRP5 (low-density lipoprotein receptorrelated protein 5). Human genome encodes for about
). This serine-threonine kinase is part of a multi-protein complex together with APC, Axin, Conductin, ␤-catenin and casein kinase II (CKII). A functional APC helps maintain this complex in which GSK3␤ comes in close conduct and phosphorylates ␤-catenin either directly or through activation of CKII. Phosphorylated ␤-catenin interacts with the F box protein ␤TrCP (␤-transducin repeat containing protein) part of a SCF type ubiquitin ligase and is ubiquitinated and proteasome degradated
Another function of ␤-catenin involves its association with the adherens junction protein E-cadherin (Fig. 3) [44, 45] .
A third function of ␤-catenin independent of the two others as transcription factor and adherens junction component, involves inhibition of NF-B through direct interaction with this transcription factor [46] (Fig. 3) . This effect may be the cause of GSK3␤ requirement for NF-B activation [47] . 
K-ras initiated pathways
The oncogene K-ras has activating mutations, especially in codon 12, in about 40% to 50% of colorectal carcinomas [55, 56] [1, 4, 5] P3) production to activate Ins (1, 4, 5) P3 receptors involved in calcium signalling [65] (Fig. 4) [57] . [66] . Activation of the T␤RII and T␤RI receptors facilitates additionally an interaction with PI3-K leading to akt activation. Moreover, T␤RII/T␤RI stimulates phosphatase PP2A, an inhibitor of the kinase p70S6K. Ras may also be activated by T␤Rs either directly or through PI3-K activation [67] . [68] . [69] . Ras inhibits TGF-␤ signalling yet by another mechanism, the prevention of proteasome-mediated degradation of Smad corepressor TGIF [70] (Fig. 5) [67] . The ratio of Smad3 to akt has a correlation with the final cell fate and specifically with whether the cell will undergo apoptosis in response to TGF-␤ signalling [72] . [73] . This effect may involve inhibition of the proteasome by TGF-␤ [74] . In contrast, Ras activation promotes p27 phosphorylation at threonine 187, an event leading to ubiquitination of p27 by E3 ubiquitin ligase SKP2 and proteasome degradation [73] . [76] . In vivo compound heterozygote mice for APC and Smad4 develop more malignant polyps than APC mutants alone [77] .
The TGF-␤ pathway
Ligation of TGF-␤ to its cell surface receptor complex T␤RII and T␤RI initiates a signal transduction pathway by activating the proteins Smad2 and Smad3 (RSmads), which in conjunction with the co-activator Smad4 (also known as DPC4-deleted in pancreatic carcinoma 4) co-operate with other transcription factors for the transcription of target genes. Smad6 and Smad7 are inhibitory type Smads that inhibit RSmad mediated transcription (Fig. 5). Seven different T␤RIs and five T␤RIIs exist in vertebrate cells and may associate with each other in multiple combinations
Further inter-relations exist between TGF-␤ and Ras pathways. Activation of the MAPK/ERK pathway by Ras leads to inhibition of the TGF-␤/Smad pathway by proteasome degradation of Smad4
Jab1, Roc1 and Smurfs are the E3 ligases mediating degradation. Mutations of Smads have the same effect inactivating TGF-␤ signalling by their targeting to proteasome degradation
TGF-␤ pathway has opposite to the Ras/MAPK pathway effects in the regulation of the cell cycle in a non-transcriptional level through stabilization of the cyclin-dependent kinase inhibitor p27
An interaction of the TGF-␤/Smad pathway with the Wnt/␤-catenin pathway exists in several levels. The protein axin, which constitutes part of the ␤-catenin/GSK-3␤/APC/axin complex interacts with Smad3 and facilitates its activation [75] probably integrating signals of an adaptor function of axin for Smad3, which promotes interaction of Smad3 with the T␤R complex. In the level of transcription a cooperation of Smads with ␤-catenin/TCF4 in the activation of target genes has been observed
Obviously interactions of the two systems may occur indirectly, for example, because of interactions of both with Ras initiated pathways.
In a proposed model of TGF-␤ target gene modification, the wide array of target genes is divided in three categories [78, 79] [81] . T␤RII is mutated more frequently in cases with microsatellite instability due to the presence of a polyadenine repeat in its coding sequence, which makes it prone to replication errors [82] . In microsatellite stable tumours T␤RII mutations are less frequent [83] . Mutations in Smad2 are also rare (about 6% of cases) in human colorectal cancer [84] [98] . [114] . ␤-subunits ␤5, ␤2 and ␤1 harbour the chymotrypsin, trypsin and peptidyl-glutamyl activity of the proteasome, respectively [115] . The importance of the three protease activities of the proteasome varies depending on the substrate protein [116] .
binds as a tetramer to specific DNA sequences comprised by the base sequence RRRC(A/T)(T/A) GYYY (where R is a purine and Y is a pyrimidine) through its central DNA binding domain (amino-acids 102-292). Non-specific interactions of the carboxy-terminal part of p53, through three lysine residues to several
Several The Ubiquitin-proteasome system in apoptosis and the cell cycle [152, 153] [154, 155] . Probably IAPs in this manner represent a safeguard mechanism that neutralizes accidental release of Smac/Diablo [156] and other promoters of apoptosis such as AIF (apoptosis inducing factor) and HtrA2/Omi [155, 157] from the mitochondria to the cytoplasm in non-apoptotic conditions. When apoptosis is triggered by external or internal stimuli this mechanism is over-ridden and activation of caspases cannot be prevented by IAPs [158] .
The critical role of the ubiquitin-proteasome system in regulation of both apoptosis and the cell cycle is worth further discussion. This role is expected from a review of the list of most studied proteasome substrate proteins. Direct and indirect proteasome influences in both critical processes have been revealed. Two distinct pathways for apoptosis termed extrinsic and intrinsic have been described [149]. The extrinsic pathway starts from cell surface death receptors, which recruit and activate up-stream caspases and mainly caspase-8, which in their turn activate executioner caspases-3 or -7 [150]. The intrinsic pathway is triggered by mitochondrial perturbation, which results in release of cytochrome c, apaf-1 and Smac/Diablo. Inhibition of the apoptosis inhibitors (IAPs) is relieved and the up-stream caspase-9 is activated to activate again executioner caspases. The UPS is involved in the regulation of core apoptosis machinery. Pro-apoptotic bcl-2 family member Bax, Bad, Bid and Bik, as well as Smac/Diablo and IAPs are proteasome substrates. All members of the conserved family of IAPs possess BIR (bacilovirus inhibitor of apoptosis repeat) domains and in fact by definition any protein that contains a BIR domain belongs to the IAP family [151]. BIR domains represent a cysteine rich motif of about 65 amino-acids that mediates interaction of IAPs with caspases and leads to caspase inhibition. IAPs contain also a RING domain, which allows interaction with E2 ubiquitin conjugating enzymes, a function that characterizes the E3 enzyme activity of IAPs
. Through this activity IAPs inhibit and promote degradation of Smac/Diablo but in addition their own auto-ubiquitination and proteasomal degradation. Both the IAP/Smac and IAP/caspases interactions involve BIR domains of IAPs and in the case of Smac a so-called IBM (IAP-binding motif) four amino acids domain and a homologous to IBM domain in the linker region in the case of caspases
An additional molecule that can interact and inhibit IAPs in a manner analogous to Smac/Diablo and HtrA2/Omi is the elongation factor GSPT1/eRF. This polypeptide can be processed to a fragment that is released from its initial site, the endopasmic reticulum-associated microsomes and bind IAPs in the cytoplasm inhibiting their interaction with caspases [159]. The IAPs/GSPT1 interaction associates apoptosis with the RNA translation machinery.
A reciprocal interaction by which caspases activation during apoptosis inactivates proteasome, has been described [160, 161] [160, 161] . Indeed the fact that activated executioner caspases degrade proteasome components leading to proteasome inhibition points to a crucial role of proteasome in cell survival that needs to be circumvented in order for apoptosis to proceed [162] . This happens despite the role that the proteasome plays in degrading IAP member XIAP and cIAP1 after a RING domain reciprocal interaction [163] .
. Specifically the chymotrypsin-like and peptidyl-gloutamyl proteasomal activities are affected due to degradation of the 19S subunits Rpt5 and Rpn10 involved in substrate recognition and Rpn2 involved in holding together the lid and base components of the 19S proteasome
Both p53 itself and its co-factor ASPP2/53BP2 are proteasome substrates [119] and given that these factors have a crucial role in inducing apoptosis, this constitutes an additional regulatory role of UPS in apoptosis [164, 165] .
The role of the ubiquitin-proteasome pathway in cell cycle regulation has recently begun to emerge [166] . Two types of E3 ligases the APC/C (anaphase promoting complex/cyclosome) and the SCF (Skp1/Cullin/F-box protein) related type ligases are involved in cell cycle regulation [167] . During [168] . Cyclin B, considered the master regulator of mitosis, which composes together with cdc2 the mitosis-promoting factor (MPF) is also a substrate for ubiquitination by APC/C [169] . [170] . Metastatic colorectal tumour tissue displays lower p27 immunostaining than corresponding primary tumours [171] . E3 ubiquitin ligase skp2 (S phase kinase-associated protein 2) and its co-factor cks1 (Cyclin kinase subunit 1), which are involved in p27 ubiquitination and subsequent degradation by the proteasome, are over-expressed in less differentiated colorectal tumours [172, 173] [175] . [179] [180] [181] [182] (Fig. 7) . Co-operation of ERK1 and ERK2, p38/MAPK and NF-B is required for transcription of Cox-2 by protease activated receptors [183] and is involved in Cox-2 induction by interferon ␥ [184] and exogenous carcinogens [185] in various cell types. [189] . Additionally a peroxisome proliferator response element (PPRE) is present on Cox-2 promoter [190] and is responsive to PPAR␣ but not PPAR␥ stimulation [191] . Post-transcriptionally a role for translational silencer TIA-1 has been suggested [192, 193] 
MPF phosphorylates mitotic regulating proteins in order for a cell to get through the G2 phase to mitosis. When mitosis is completed cyclin B is ubiquitinated by APC/C to be degraded by the proteasome and the cell exits mitosis to G1.
Proteasome inhibition in colorectal carcinoma
As evident from the above discussions, key components of all four major molecular pathways involved in the pathogenesis of colorectal carcinoma (␤-catenin, Smad4, p53 and NF-B downstream of Ras) are regulated by the ubiquitin-proteasome system. Pharmaceutical (or other) proteasome inhibition would be expected to have anti-oncogenic effects by stabilizing tumour suppressors Smad4 and p53 and inhibiting anti-apoptotic and drug resistance promoting NF-B. On the other hand stabilization of anti-apoptotic ␤-catenin is already taking place in most colorectal cancer tissues irrespective of proteasome inhibition due to APC debilitating mutations. Moreover, as discussed in the relevant section, ␤-catenin up-regulation may have tumour-suppressing properties due to non-transcriptional functions. Despite the fact that proteasome has a variety of substrates both pro-apoptotic and pro-survival, its dysfunction or inhibition is expected to have profound effects in cell homeostasis and push the balance towards apoptosis especially in unstable neoplastic cells. This hypothesis is supported by the fact that the proteasome is inhibited by caspases, executing apoptosis. p27 a cdk inhibitor is an important regulator of cell cycle and a proteasome substrate. It has been found to be down-regulated by increased proteasome activity in colorectal cancer
Cox-2 in colorectal cancer
The importance of cox-2 enzyme (Cyclo-oxygenase 2 or Prostaglandin endoperoxidase H synthase 2) in the pathogenesis of colorectal cancer became evident in a serendipitous manner when it was found that patients with hereditary polyposis coli treated with non-steroidal anti-inflammatory drugs had regression of colonic polyps [176]. Cox-2 is hyperexpressed in the majority of colon cancers as well as in a variety of other cancer locations such as head and neck, breast, cervix, bladder, gastric and elsewhere [177]. Colorectal carcinomas in other primates display also increased expression of Cox-2 [178]. Its gene is a transcriptional target of both ␤-catenin/TCF4 and NF-B transcription factors as well as k-ras downstream transcriptional programs
NF-B and p38/MAPK but not ERK1/2 are involved in the induction of Cox-2 by interleukin-1␤ [186]. Transcription factor AP1 stimulates Cox-2 transcription and its inhibition suppresses Cox-2 expression [187]. An IL-6 regulatory element binding NF-IL6 and a CRE (cAMP-response element) are both present in the promoter of cox-2 gene. The NF-IL6 site is also important for Cox-2 induction by Ets family transcription factor PEA3 [188]. An NFAT (nuclear factor of activated T cells) response element on Cox-2 promoter is responsible for Cox-2 induction in colorectal cancer cells
. Cox-2 mRNA has an AU-rich element (ARE) in its 3'-untranslated region (3'-UTR) which binds TIA-1 and results in the inhibition of mRNA translation.
The cox-2 protein is the inducible form of the enzyme that catalyzes, by a cyclo-oxygenase and an endoperoxidase action, the conversion of arachidonic acid [5, 8, 11, 14 eicosatetraenoic acid) to prostaglandin G2 (PGG2) and PGH2, which is finally converted by specific prostaglandin synthases to different prostaglandins (PGE2, PGD2, PGF2, PGI2 and TXA2) [194] (Fig. 8) . These lipid metabolites are transported outside the producing cell by the ATP binding cassette family transporter MRP4 (multi-drug resistance protein 4) [195] and, through ligation with their cognate receptors, have various pro-survival, proliferative and pro-angiogenic effects in an autocrine and paracrine mode of action [196, 197] . Prostanoid receptors belong to the rhodopsin-type super-family and have seven trans-membrane domains [198] . Prostaglandin amounts entering the circulation are rapidly removed by enzymatic inactivation during their first lung passage [199] [203] . Nevertheless, the role of PPAR␤/ in colon carcinogenesis is still controversial and other investigators find a tumour suppressive effect [204, 205] [206, 207] . In this way a positive feed-forward loop is perpetuated in the cancer cell as ␤-catenin activity results in further EGFR transactivation [208] .
PGE2 produced by colorectal tumour cells has tumour-promoting effects by affecting the immune system [209] [214] . [215] .
15PGDH is normally a TGF-␤ induced gene and as a result dysfunction of this pathway in colorectal cancer may underlie decreased 15PGDH expression
Although cox-2 is regulated by a variety of transcription factors, the fact that it is found up-regulated even in early stages of colorectal carcinogenesis and that it is hyper-expressed in all cell lines with a mutant APC, underlines the importance of Wnt/␤-catenin/TCF4 pathway in its regulation.
Cox-1, the constitutively expressed form of the enzyme that catalyzes conversion of arachidonic acid to PGH2 has a high homology and remarkably similar tertiary structure with cox-2 but a different regulation of expression [216] . A role for cox-1 in the formation of polyps smaller than 1 mm in size in a mouse model of intestinal polyposis has been reported whereas cox-2 was induced in larger polyps [217] . This may be related to both the level of prostaglandin production and arachidonic acid depletion, which may be sufficient with the cox-1 action to sustain small sized polyps but needs the robust inducible cox-2 action in larger polyps.
Cox-2 and lipid metabolism in colorectal cancer
Arachidonic acid is the substrate of Cox-2. Arachidonic acid utilization by cox-2 leads to a decrease in its level and in consequence a decrease in the level of the pro-apoptotic lipid ceramide and increase of anti-apoptotic bcl-2 inhibiting apoptosis by an additional molecular pathway [218] . A similar effect is observed with the action of the enzyme FACL4 (fatty acid CoA ligase 4) that depletes free arachidonic acid by catalyzing its conjugation with co-enzyme A (Fig. 9) and activation for esterification [219, 220] . The pro-apoptotic role of arachidonic acid inside the neoplastic cell is further highlighted by the fact that FACL4 is over-expressed in colon adenocarcinoma [221] and other carcinomas [222] .
Unesterified arachidonic acid promotes production of pro-apoptotic ceramide by activating hydrolysis of sphingomyelin [223] . Besides apoptosis promotion, ceramide induces expression of cox-2 [224] in a homeostatic mechanism that will lead to utilization of arachidonic acid.
A pathway of arachidonic depletion is important for the neoplastic colorectal cell because free arachidonic production may be increased due to activation of phospholipase A2 (PLA2), the enzyme that performs the reverse to FACL4 function, by activated MAPK [225, 226] . Cox-2 inhibition has the potential of both blocking the generation of prostaglandins and promoting accumulation of unesterified arachidonic acid, actions that lead to cellular demise. Nevertheless, knocking out cytoplasmic PLA2 in APC mutated mice decreases the size [227] and number [228] of polyps in the small intestine despite the fact that it is predicted to deplete rather than increase free arachidonic acid. These results parallel the decreased polyps in double APC and Cox-2 knock out mice [229] and underscore the role of prostaglandins in colon carcinogenesis. The proapoptotic role of arachidonic acid is far from being nullified by these results and its increased levels which are more evident in conditions of cPLA2 activation and Cox-2 inhibition promote opening of the mitochondrial permeability transition pores and release of pro-apoptotic proteins [230] . Furthermore, a high Cox-2 and low cPLA2 phenotype has been found by immunohistochemistry in high-risk patients [231] . [233] . [234] and may play a role in the non-Cox mediated induction of apoptosis by NSAIDs [235, 236] . Nevertheless, decreased expression of the enzyme in colon cancer has been also reported [237] . The leukotriene synthesizing enzyme 5-LOX is implicated in cell proliferation [238, 239] and combined Cox-2 and 5-LOX inhibitors are interesting novel drugs with potential colon cancer therapeutic activity beyond that seen with single enzyme inhibition [240] . Another cox-independent action of cox inhibitors that promotes apoptosis is the induction of the enzyme spermidine/spermine acyl-transferase (SSAT) the major catabolic enzyme of oncogenic polyamines [248] . Natural polyamines putrescine, spermidine and spermine promote cell proliferation by inducing c-myc, c-fos, c-jun [245] and several proteine kinases genes [249] . A direct interaction of polyamines with DNA has been described [250] . In contrast a decrease of polyamines by a specific inhibitor of their synthesis, DFMO (␣-difluoromethylornithine) leads to cell growth inhibition and cell cycle arrest [251] and an increase of JunD mRNA and DNA binding activity [252] . JunD is a member of the AP-1 transcription factor complex, which in contrast to other members, c-Jun and JunB, promotes cell cycle arrest. Thus, the induction of SSAT, which transforms spermidine and spermine to their Nacetyl derivatives by aspirin, sulindac sulfone and other NSAIDs promote apoptosis in colorectal cancer cells [253] [254] [255] . SSAT induction is mediated by PPAR␥ transcription factor ligated by sulindac [253] . SSAT gene has two PPRE (PPAR response elements) in its promoter, one of which is required for PPAR␥ binding [256] . Several other NSAIDs such as indomethacin, ibuprofen and flufenamic acid have been found to be ligand activators of PPAR␥ [257] . This transcription factor inhibits colorectal cell proliferation directly [258] and indirectly by suppressing tumour angiogenesis [259] . [261, 262] . Transfection of the cells with a NAG-1 containing plasmid induced also apoptosis. NAG-1 is a p53 target gene [263, 264] 
Lipoxygenase enzymes (LOX) play also a role in the metabolism of arachidonic acid as well as its dietary precursor, linoleic acid. 15-LOX-1 metabolizes mainly linoleic acid to 13-S-HODE (13-SHydroxy-octadeca-dienoic acid) while its homologue 15-LOX-2 metabolizes arachidonic acid to 15-S-HETE (15-S-Hydroxy-eicosa-tetraenoic acid) [232]. Other LOXs having arachidonic acid as a substrate include 12-S-LOX, 12-R-LOX, 8-LOX and 5-LOX, the first enzyme of the pathway that leads to the production of leukotrienes. Additional LOXs may exist
The role of LOXs in colon carcinogenesis is far from clear, despite their obvious role as enzymes involved in arachidonic metabolism. 15-LOX-1 is found to be hyper-expressed in colorectal cancer
Cox-independent anti-carcinogenic effects of Cox inhibitors
but its induction by NSAIDs is not p53-dependent, nor correlates with their
Cox inhibition potency [261] .
Sulindac and other NSAIDs inhibit phosphorylation and activation of the kinases ERK1 and ERK2 leading to inhibition of phosphorylation of the proapoptotic bcl2 family member Bad and in inhibition of the anti-apoptotic effects of ERKs [265] . Although this action of NSAIDs may be Cox-dependent through inhibition of PGE2 initiated EGFR transactivation up-stream of ERKs, it has been observed in both cells expressing and not expressing Cox-2 [266] and thus it must be considered at least in part a Coxindependent pro-apoptotic mechanism of Cox inhibitors. [262] . Rac1 has a role in colon epithelium differentiation and it is expressed in colon epithelial cells at the villus tips.
Rac1 a member of the Rho family of small GTPases related to Ras is induced after aspirin treatment of colon cancer cells
Degradation of ␤-catenin has been observed after NSAIDs incubation in colorectal cancer cells cultures [267] and in vivo in Min mice [268] and may be an additional mechanism of Cox-independent apoptosis promotion. ␤-catenin degradation is APC-independent as it has been noticed in SW480 bi-allelic APC mutant cells. Other invastigators have found an inhibition of ␤-catenin-dependent transcription after aspirin and indomethacin treatment but at the same time an increase in phosphorylated ␤-catenin [269] . [195] . Several NSAIDs have been found to inhibit prostaglandin transport [270] [195] . [219] .
Prostaglandins need to be transported outside the producing cells to bind their cell membrane receptors and exert their functions. This function, as mentioned, is executed by the transporter MRP4
The transcription factor NF-B has a central role in favouring proliferation, inhibiting apoptosis and mediating chemotherapy resistance and is activated in colorectal cancer cells [146] . Combined treatment by a cox and proteasome inhibitor inhibits NF-B activity through several mechanisms. Proteasome inhibition stabilizes the NF-B inhibitor I-B, a proteasome substrate. Moreover it stabilizes ␤-catenin, which through direct interaction with NF-B inhibits its activity [46] . Cox inhibitors inhibit directly the kinase IKK, an effect that may mediate cox-independent anti-proliferative effects of Cox inhibitors [247] [284, 285] . ODC is a gene target of c-myc and this fact may explain its up-regulation in cells with APC mutations [255] and activated K-ras [286] . ODC is also a substrate of the proteasome and proteasome's pharmaceutical inhibition may further increase its levels in colorectal cells with the final result of increasing polyamine production. This untoward effect can be inhibited by simultaneous induction of the enzyme SSAT by Cox inhibitors as previously discussed [287] .
As a result of anti-proliferative and pro-apoptotic cooperation in multiple levels as well as independent effects of each, combined cox and proteasome inhibition represents a particularly promising avenue to explore in the treatment of colorectal cancer. The concept of combined targeted therapy has been a promising one. It has been investigated using combinations of NSAIDs [288] [289] [290] [291] or bortezomib [292, 293] 
